New drug combo shows promise in early breast cancer trial
NCT ID NCT07017673
First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 4 times
Summary
This study tests whether adding the drug ivonescimab to standard chemotherapy before surgery can improve outcomes for people with early-stage triple-negative breast cancer. About 34 participants will receive the combination every three weeks for six cycles, then undergo surgery. The main goal is to see if the cancer disappears completely by the time of surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY STAGE TRIPLE-NEGATIVE BREAST CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cedars-Sinai Medical Center
RECRUITINGLos Angeles, California, 90048, United States
-
Cedars-Sinai Medical Center Beverly Hills
RECRUITINGLos Angeles, California, 90211, United States
-
Hunt Cancer Institute, an Affiliate of CS Cancer
RECRUITINGTorrance, California, 90505, United States
-
Huntington Cancer Center, an Affiliate of CS Cancer
NOT_YET_RECRUITINGPasadena, California, 91105, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a High-Fiber diet shield the gut during breast cancer therapy?
- Can Gene-Edited immune cells tame Hard-to-Treat cancers?
- Can a One-Time Anti-Inflammatory shot during surgery curb Triple-Negative breast Cancer's return?
- Triple-Drug cocktail aims to stall aggressive breast cancer
- Could a vaccine stop Triple-Negative breast cancer from coming back?
- Engineered immune cells take aim at Mesothelin-Positive tumors